AstraZeneca to invest in new biologics manufacturing facility in SwedenStaff writer ▼ | May 19, 2015
AstraZeneca plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden.
Pharma The new plant will be focused on protein therapeutics
Södertälje is currently home to AstraZeneca's largest global tablets and capsules manufacturing facility and is also a launch platform site for the company, with specialist capabilities on-site that allow large-scale production of new medicines, working closely with the research and development organisation.
By locating the new manufacturing plant in Södertälje, the company will combine its expertise in biologics with the well-established culture of operational excellence that exists within the Sweden Operations unit.
The planned investment will, subject to relevant approvals by the local authorities, create between 150 and 250 highly skilled new roles at AstraZeneca by 2019.
The $285 million planned investment is the first phase of a potential three-part programme to expand AstraZeneca's biologics manufacturing capabilities. Further investment decisions are expected to be made in the coming years. ■